Re: HCLS chartering/next steps Thur 16 June

Some suggestions for the Use Cases document:

1.  Change the title of the "Pharma Co-vigilence" section to the
"Healthcare Quality Measurement and Pharmacovigilence"

2. Add a section:
[[
Personalized Medicine

The ability to connect previously disparate healthcare research and
outcomes information with patient profiles will enable care providers to
tailor their treatment plans to yield the best expected outcome for each
individual patient.  Semantic web technology facilitates this by
enabling information that is expressed in disparate vocabularies and
formats to be connected with high semantic fidelity.
]]

David

On Wed, 2011-06-15 at 20:58 -0400, Eric Prud'hommeaux wrote:
> Hi again again. Since last we met, I pushed some documents around and
> piled some words into others. The High Level Use Cases (AKA elevator
> pitches) doc is now on the wiki:
>   http://www.w3.org/wiki/HCLSIG/HighLevelUseCases
> The on-deck charter remains where it was:
>   http://www.w3.org/2011/05/HCLSIGCharter-proposal
> Scott wrote up a brag sheet to show what we accomplished in this charter:
>   http://www.w3.org/wiki/HCLSIG/Products
> and I wrote a narrative version catering to pharmas:
>   http://www.w3.org/wiki/HCLSIG/Products/TranslationalMedicine
> Join me tomorrow at the usual time (11.00 EDT, 15.00Z)?
> 
> * Eric Prud'hommeaux <eric@w3.org> [2011-06-01 22:06-0400]
> > Hi all again. Last week we had some good idea exchange about what we
> > should put into the next HCLSIG charter, i.e. what we tell the world
> > we are doing. We agreed that we weren't done and that we'd like to
> > meet in one week. I invite all to meet tomorrow, Thursday 2 June.
> > Details at the bottom of the message.
> > 
> > * Eric Prud'hommeaux <eric@w3.org> [2011-05-23 23:04-0400]
> > > Hi all, as some of you reallize, the charter ends at the end of this
> > > month. I've been polling around to see what alternative formulations
> > > would give us the most resources and impact. In the process, I wrote
> > > up some of our high-level use cases (elevator speeches) to help us
> > > approach the relevant parties in pharmas, health services and
> > > research: <http://www.w3.org/2011/05/HCLSIGUseCases>.
> > > 
> > > I'd like to discuss the landscape and potential strategies with the
> > > community. I'd particularly like to invite those who have been active
> > > or see themselves as being active in the next incarnation of the group.
> > > We'll discuss the current, fairly conservative draft charter
> > > <http://www.w3.org/2011/05/HCLSIGCharter-proposal>, as well as ways to
> > > optimize both its message and the paths for dissemination. An example
> > > of a messaging alternative would be to characterize the HCLS IG work
> > > in terms of e.g. overarching translational medicine use cases:
> > > "
> > >   The W3C Semantic Web in Health Care and Life Sciences Interest Group
> > >   focuses on translational medicine use cases. The group will continue
> > >   the aggregation of cutting edge and traditional scientific knowledge
> > >   to meet use cases for researchers, care givers, patients and
> > >   regulatory agencies. Due to the scope and diversity of expertise
> > >   required to meet translational needs, the HCLS IG work is broken
> > >   down into discrete task forces focused on particular data
> > >   acquisition, modeling and integration requirements:
> > > 
> > >   Terminology - identifying and integrating identifiers for biological
> > >   processes, gross anatomy and medical procedures to promote
> > >   unification of domain data.
> > > 
> > >   LODD - curation of compounds, clinical trials and outcomes.
> > > 
> > >   BioRDF - modeling of biological processes and actors.
> > > 
> > >   Scientific Discourse - representation and tracking of the changing
> > >   landscape of scientific knowledge and the driving theora and
> > >   experiments.
> > > 
> > >   Translational Medicine - the oversight and high-level ontology that
> > >   connects these disciplines together in order to meet immediate and
> > >   long term needs from pharma, health care and other vested parties.
> > > "
> > > . Perhaps you all have some other ideas about how to tell a story
> > > about our work which will serve to both draw people to our work and
> > > our products and to help already interested parties find the task
> > > forces which interest them. I of course want to draw an optimal
> > > balance between doing work which motivates the participants and
> > > focusing on tasks which will accelerate education and adoption by
> > > important organizations.
> > > 
> > > I'm sure you are all aware of my preference for technical work, but I
> > > feel that this outreach can make us all ultimately more effective. I
> > > will use the Thursday 26 May HCLS slot (11:00 EDT) to reach out to the
> > > current HCLS IG community, and whomever else you folks elect to bring
> > > along. Of course, I'll reserve extra teleconference slots, but please
> > > RSVP to me privately so I can make a guess at how many ports to
> > > reserve. Also, please provide what feedback you can before the
> > > conference. Anything we take care of before will make the meeting more
> > > efficient.
> > > 
> > > Conference Details
> > > 
> > > Date of Call:xThursday,xMayx26,x2011x
> >                 Thursday, June 2, 2011
> > 
> > > Time of Call: 11:00 am Eastern Time, 4 pm UK, 5 pm CET
> > > Dial-In #: +1.617.761.6200 (Cambridge, MA)
> > > [Note: limited access to European dial in numbers below]
> > > Dial-In #: +33.4.26.46.79.03 (Nice, France)
> > > Dial-In #: +44.203.318.0479 (Bristol, UK)
> > > Participant Access Code: 4257 ("HCLS")
> > > IRC Channel: irc.w3.org port 6665 channel #HCLS (see W3C IRC page for
> > > details, or see Web IRC), Quick Start: Use
> > > http://www.mibbit.com/chat/?server=irc.w3.org:6665&channel=%23hcls for
> > > IRC access.
> > > Duration: ~1 hour
> > > Convener: Eric Prud'hommeaux
> > > Scribe: TBD
> > > 
> > > HCLS IG charter/strategy discussion
> > > -- 
> > > -ericP
> > 
> > -- 
> > -ericP
> 

-- 
David Booth, Ph.D.
http://dbooth.org/

Opinions expressed herein are those of the author and do not necessarily
reflect those of his employer.

Received on Thursday, 16 June 2011 16:11:21 UTC